^
    Back
    Association details:
    Biomarker:ROS1 fusion
    Cancer:Melanoma
    Drug:Rozlytrek (entrectinib) (ALK inhibitor, TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor, ROS1 inhibitor, JAK2 inhibitor, TNK2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Fusions in ALK and ROS1, more common in lung cancer, occur uncommonly (>1% incidence) across subtypes of melanoma. Fusions in these genes may predispose to clinical activity from inhibitors of these genes (eg, crizotinib and entrecitinib)
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    New
    Title:

    entrectinib (Rozlytrek®) is accepted for use within NHSScotland.

    Excerpt:
    entrectinib (Rozlytrek®) is accepted for use within NHSScotland...Indication under review: as monotherapy for the treatment of adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers.

    Excerpt:
    ...Confirmed diagnosis of a ROS1 gene fusion-positive malignancy, other than NSCLC, that has been identified using an analytically validated sequencing technique....
    Trial ID:
    DETERMINE
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Comp Eff Res
    Title:

    Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer

    Published date:
    07/10/2020
    Excerpt:
    To perform indirect treatment comparisons of entrectinib versus alternative ROS1 fusion-positive non-small cell lung cancer treatments…These results suggested improved outcomes with entrectinib versus crizotinib/chemotherapy and may help to make better informed treatment decisions.
    DOI:
    10.2217/cer-2020-0063